USPTO serial 79429785
AELIS FARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- FERRELL, LUCY K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with AELIS FARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Evaluations and assessments of the goods of others in the scientific, pharmaceutical, pharmacological, biological, biotechnological, biochemical and clinical fields to assure compliance with industry standards, therapeutic efficiency, and patient tolerability; research and development in the pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical and clinical fields; pre-clinical and clinical research in the field of neurology, psychiatry, dermatology, addictology, and pathology; pre-clinical and clinical research in the field of behavioral disorder treatment, cognitive disorder treatment, and metabolic syndrome treatment; preclinical and clinical research in the field of endocannabinoid system-dependent diseases; conducting clinical trials for others related to pharmaceuticals; scientific research for medical purposes in the field of neurology, psychiatry, dermatology, addictology, and pathology; scientific research for medical purposes in the field of behavioral disorder treatment, cognitive disorder treatment, and metabolic syndrome treatment; scientific research for medical purposes in the field of endocannabinoid system-dependent diseases; design, testing and development of molecules and new molecular entities for therapeutic purposes; scientific laboratory services; chemical and biochemical analyses; providing scientific analyses related to pharmaceutical and medicated preparation design; testing of new pharmaceutical products for third parties; provision of information related to scientific research in pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical and clinical fields; providing and making available scientific information to third parties in the field of clinical and pre-clinical trials; providing information to third parties concerning results of clinical trials for medical and pharmaceutical products | ACTIVE | — |
| 045 | Licensing services regarding intellectual property rights in the pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical, molecular and clinical fields; intellectual property licensing services for research and development in pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical, molecular and clinical fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AELIS FARMA
- Other trademarks owned by AELIS FARMA
- Other trademarks owned by AELIS FARMA
- Other trademarks owned by AELIS FARMA
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named AELIS FARMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 11, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 5, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 15, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 27, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 27, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 31, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 30, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 30, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 29, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 29, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 29, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 13, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Aug 7, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |